3 New Strong Buy Ratings from Top-Rated Analysts: 10/16/2026
Here’s a peek at the latest picks from our Strong Buy Stocks from Top Wall Street Analysts screener:
- Precigen (PGEN): FDA-approved launch tracking ahead, 140% upside target
- Semtech (SMTC): Six top-1% analysts back this data center play
- Penguin Solutions (PENG): AI memory momentum with three Strong Buy ratings
P.S. Get more alerts like this daily … Try WallStreetZen Premium.
A note from our sponsors...
Where Investors Can Still Find 10X Opportunities
Some of the biggest investment gains come from small, overlooked markets. Legendary international speculator Doug Casey has spent more than 50 years looking for exactly these situations. In a new free report, he reveals 3 contrarian stocks he likes right now – and why he believes some neglected corners of the market could still offer 10X, even 100X, upside.
Click here to get your free copy.
1. Semtech Corporation (NASDAQ: SMTC)
With strong execution momentum, expanding partnerships in SiGe technology for data centers, and robust demand for its 1.6T product ramp, this semiconductor company is well-positioned to capitalize on the ongoing infrastructure buildout supporting AI workloads.
Zen Rating: A (Strong Buy) — see full analysis
Recent Price: $155.48 — get current quote
Max 1-year forecast: $300.00
Why we're watching:
- SMTC has strong, bullish coverage among the analysts we track, with 8 Strong Buy, 7 Buy, and 1 Hold recommendations. See all recommendations here
- UBS researcher Timothy Arcuri (a top 1% rated analyst) maintained his Strong Buy recommendation with a price target over 30% over current levels.
- More exciting still, For example, Baird researcher Craig Ellis (a top 1% rated analyst) maintained his Buy recommendation with a price target suggesting over 70% upside potential from current levels, citing pricing power and innovative products as drivers of future revenue.
- Four additional top 1% analysts all maintain bullish outlooks on the semiconductor sector's growth and SMTC in particular.
- Industry ranking context: SMTC is currently the #3 highest-rated stock in the Semiconductor industry, which has an Industry Rating of A.
- Zen Ratings highlights: SMTC earns an overall A rating, which amounts to a Strong Buy recommendation. Stocks in this topmost tier have historically delivered nearly 30% annual returns, soundly beating the S&P.
- Component Grades: SMTC excels with an A for Growth and strong Bs for Financials, Momentum, Safety, and Sentiment, a combination that reflects both solid execution and attractive growth prospects in the data center connectivity market. See all 7 Component Grades here
2. Penguin Solutions (NASDAQ: PENG)
This global technology company is capitalizing on accelerating momentum in its Advanced Computing and Integrated Memory product lines, positioning it to benefit from the ongoing AI-driven data center buildout.
Zen Rating: B (Buy) — see full analysis
Recent Price: $66.80 — get current quote
Max 1-year forecast: $100.00
Why we're watching:
- PENG has solid, bullish coverage among the analysts we track, with 3 Strong Buy, 2 Buy, and 1 Strong Sell recommendations. See all recommendations here
- It has a slew of fresh recommendations, including Strong Buys from Stifel Nicolaus researcher Brian Chin (a top 1% rated analyst); Rosenblatt researcher Kevin Cassidy (a top 1% rated analyst) raised his price target, predicting solid beats-n-raises for both Q3 and Q4 2026, supported by accelerating momentum in the company's Advanced Computing and Integrated Memory product lines. The current street-high estimate suggests the stock could see nearly 50% upside in the coming year.
- Industry ranking context: PENG is currently the #7 highest-rated stock in the Semiconductor industry, which has an Industry Rating of A.
- Zen Ratings highlights: PENG earns an overall B rating, which is equal to a Buy recommendation. Stocks with this rating have historically beaten the S&P annually.
- Component Grades: PENG stands out with an A for Growth and solid Bs for Momentum and Sentiment, reflecting strong analyst confidence and accelerating revenue trends in the AI infrastructure space. See all 7 Component Grades here
3. Precigen (NASDAQ: PGEN)
Precigen is an American gene and cellular therapy company that has recently gained FDA approval for the sole approved treatment for adult recurrent respiratory papillomatosis. With commercial launch tracking ahead of recent rare oncology releases and strong Q2 sales momentum, the company is positioned at an inflection point as it transitions from development to commercialization.
Zen Rating: A (Strong Buy) — see full analysis
Recent Price: $7.30 — get current quote
Max 1-year forecast: $18.00
Why we're watching:
- PGEN has limited, but overall bullish, coverage among the analysts we track, with 1 Strong Buy and 2 Buy recommendations. See all recommendations here
- For example, B. Riley Securities researcher Yuan Zhi (a top 8% rated analyst) initiated coverage with a Strong Buy recommendation and a price target representing over 60% upside potential from current levels, highlighting that Papzimeos' commercial launch is tracking ahead of recent releases in rare oncology.
- Even more exciting, HC Wainwright & Co. researcher Swayampakula Ramakanth (a top 3% rated analyst) maintained his Buy recommendation with a price target 140% above current levels.
- Our Editor-in-Chief highlighted PGEN as one of his Trade of the Week picks in his most recent no-paywall webinar … To gain access to his next picks, sign up at wallstreetzen.com/live.
- Industry ranking context: PGEN is currently the #2 highest-rated stock in the Biotech industry, which has an Industry Rating of F.
- Zen Ratings highlights: PGEN earns an overall A rating, which amounts to a Strong Buy recommendation. Stocks with this rating represent the elite top 5% of all 4,600+ stocks tracked based on a rigorous 115-factor fundamental review.
- Component Grades: PGEN excels with strong As for Growth, Momentum, and Sentiment, along with a B for Artificial Intelligence, reflecting the company's promising pipeline and accelerating commercial traction in the gene therapy space. See all 7 Component Grades here
What to Do Next?
Want to get in touch? Email us at news@wallstreetzen.com.
Keep Reading
See All News
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterInformation is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.